Sprint Bioscience announced in a press release on July 23 that the company has entered into an agreement with Lilly TuneLab, a collaborative, AI-driven drug discovery platform created by Eli Lilly and Company (Lilly). By joining TuneLab, Sprint Bioscience intends to strengthen and accelerate the development of its portfolio through access to advanced artificial intelligence (AI) and machine learning (ML) models.

Sprint Bioscience will use Lilly TuneLab to further strengthen its capabilities in AI and ML. Through TuneLab, the company will gain access to predictive models for drug development that have been trained on decades of Lilly’s own research data. These models will complement Sprint Bioscience’s fragment-based drug design platform and established workflows with advanced AI tools that enable more data-driven decisions early in the development process. This is expected to increase both the speed and precision of the company’s preclinical programs.

TuneLab offers models in areas such as safety, pharmacokinetics, and early-stage development decisions for both small molecules and biologics. Through federated learning, participating companies can benefit from continuous improvements to the models without having to share or expose their own data.

"We are very excited to gain access to the TuneLab platform. The combination of our fragment-based approach and advanced AI models offers great opportunities to further improve the efficiency and pace of development of our programs," says Johan Emilsson, CEO of Sprint Bioscience.

The full press release can be found here.